A detailed history of Gsa Capital Partners LLP transactions in Organogenesis Holdings Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 773,547 shares of ORGO stock, worth $2.46 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
773,547
Previous 884,721 12.57%
Holding current value
$2.46 Million
Previous $2.48 Million 10.7%
% of portfolio
0.17%
Previous 0.17%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$2.42 - $3.24 $269,041 - $360,203
-111,174 Reduced 12.57%
773,547 $2.21 Million
Q2 2024

Aug 15, 2024

BUY
$2.28 - $3.03 $805,986 - $1.07 Million
353,503 Added 66.55%
884,721 $2.48 Million
Q1 2024

May 03, 2024

BUY
$2.61 - $4.49 $702,912 - $1.21 Million
269,315 Added 102.83%
531,218 $1.51 Million
Q4 2023

Feb 16, 2024

SELL
$1.97 - $4.21 $694,750 - $1.48 Million
-352,665 Reduced 57.38%
261,903 $1.07 Million
Q3 2023

Nov 15, 2023

SELL
$2.34 - $4.43 $221,462 - $419,264
-94,642 Reduced 13.34%
614,568 $1.95 Million
Q2 2023

Aug 14, 2023

SELL
$1.9 - $4.3 $31,061 - $70,296
-16,348 Reduced 2.25%
709,210 $2.35 Million
Q1 2023

May 12, 2023

BUY
$1.89 - $2.93 $986,886 - $1.53 Million
522,162 Added 256.72%
725,558 $1.55 Million
Q4 2022

Feb 13, 2023

BUY
$2.48 - $3.43 $474,689 - $656,526
191,407 Added 1596.52%
203,396 $547,000
Q3 2022

Nov 14, 2022

SELL
$3.14 - $6.43 $70,307 - $143,974
-22,391 Reduced 65.13%
11,989 $39,000
Q2 2022

Aug 09, 2022

BUY
$4.74 - $8.15 $102,052 - $175,469
21,530 Added 167.55%
34,380 $168,000
Q1 2022

May 11, 2022

BUY
$6.47 - $9.57 $83,139 - $122,974
12,850 New
12,850 $98,000
Q4 2020

Feb 03, 2021

SELL
$3.63 - $7.53 $61,539 - $127,656
-16,953 Closed
0 $0
Q3 2020

Nov 06, 2020

BUY
$3.29 - $4.58 $55,775 - $77,644
16,953 New
16,953 $65,000

Others Institutions Holding ORGO

About Organogenesis Holdings Inc.


  • Ticker ORGO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 130,888,000
  • Market Cap $416M
  • Description
  • Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokin...
More about ORGO
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.